Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Open source

DOI
10.1016/j.jmoldx.2017.11.004
Published
2018-01-23
Container
J Mol Diagn
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jmoldx.2017.11.004,
  title = {Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.},
  author = {Lindeman NI and  Cagle PT and  Aisner DL and  Arcila ME and  Beasley MB and  Bernicker EH and  Colasacco C and  Dacic S and  Hirsch FR and  Kerr K and  Kwiatkowski DJ and  Ladanyi M and  Nowak JA and  Sholl L and  Temple-Smolkin R and  Solomon B and  Souter LH and  Thunnissen E and  Tsao MS and  Ventura CB and  Wynes MW and  Yatabe Y.},
  year = {2018},
  journal = {J Mol Diagn},
  doi = {10.1016/j.jmoldx.2017.11.004},
  url = {https://doi.org/10.1016/j.jmoldx.2017.11.004}
}

RIS

TY  - JOUR
TI  - Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
AU  - Lindeman NI
AU  -  Cagle PT
AU  -  Aisner DL
AU  -  Arcila ME
AU  -  Beasley MB
AU  -  Bernicker EH
AU  -  Colasacco C
AU  -  Dacic S
AU  -  Hirsch FR
AU  -  Kerr K
AU  -  Kwiatkowski DJ
AU  -  Ladanyi M
AU  -  Nowak JA
AU  -  Sholl L
AU  -  Temple-Smolkin R
AU  -  Solomon B
AU  -  Souter LH
AU  -  Thunnissen E
AU  -  Tsao MS
AU  -  Ventura CB
AU  -  Wynes MW
AU  -  Yatabe Y.
PY  - 2018
JO  - J Mol Diagn
DO  - 10.1016/j.jmoldx.2017.11.004
UR  - https://doi.org/10.1016/j.jmoldx.2017.11.004
ER  - 

APA

NI, L., PT, C., DL, A., ME, A., MB, B., EH, B., C, C., S, D., FR, H., K, K., DJ, K., M, L., JA, N., L, S., R, T., B, S., LH, S., E, T., MS, T., CB, V., MW, W., & Y., Y. (2018). Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.. J Mol Diagn. https://doi.org/10.1016/j.jmoldx.2017.11.004

Source records